
Aktis Oncology (NASDAQ:AKTS – Free Report) – Research analysts at HC Wainwright dropped their FY2026 EPS estimates for shares of Aktis Oncology in a research report issued on Friday, November 13th. HC Wainwright analyst R. Burns now expects that the technology company will post earnings per share of ($1.97) for the year, down from their prior forecast of ($1.64). The consensus estimate for Aktis Oncology’s current full-year earnings is ($1.86) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q4 2026 earnings at ($0.60) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.66) EPS, Q3 2027 earnings at ($0.70) EPS, Q4 2027 earnings at ($0.73) EPS and FY2027 earnings at ($2.73) EPS.
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The technology company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.07). The business had revenue of $3.91 million for the quarter, compared to the consensus estimate of $4.87 million.
AKTS has been the topic of a number of other reports. Wedbush reiterated an “outperform” rating and set a $35.00 price target on shares of Aktis Oncology in a research note on Friday, October 2nd. Oppenheimer assumed coverage on shares of Aktis Oncology in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $40.00 price objective for the company. Wall Street Zen lowered Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. BMO Capital Markets started coverage on Aktis Oncology in a research report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 target price on the stock. Finally, Weiss Ratings cut Aktis Oncology from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $35.62.
View Our Latest Research Report on Aktis Oncology
Aktis Oncology Stock Down 2.8%
Shares of NASDAQ:AKTS opened at $16.16 on Tuesday. The firm’s 50-day simple moving average is $18.32 and its 200-day simple moving average is $20.77. Aktis Oncology has a fifty-two week low of $13.96 and a fifty-two week high of $34.19.
Hedge Funds Weigh In On Aktis Oncology
A number of institutional investors and hedge funds have recently made changes to their positions in AKTS. Russell Investments Group Ltd. increased its holdings in shares of Aktis Oncology by 8.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,391 shares of the technology company’s stock valued at $163,000 after purchasing an additional 637 shares in the last quarter. State of Wyoming purchased a new stake in Aktis Oncology during the second quarter worth about $32,000. The Manufacturers Life Insurance Company boosted its holdings in Aktis Oncology by 2.2% during the second quarter. The Manufacturers Life Insurance Company now owns 48,044 shares of the technology company’s stock worth $1,548,000 after buying an additional 1,051 shares in the last quarter. Global Retirement Partners LLC grew its position in Aktis Oncology by 289.1% during the third quarter. Global Retirement Partners LLC now owns 1,537 shares of the technology company’s stock worth $30,000 after buying an additional 1,142 shares during the period. Finally, GK Wealth Management LLC acquired a new position in Aktis Oncology during the third quarter worth about $26,000. 28.84% of the stock is owned by institutional investors and hedge funds.
Aktis Oncology Company Profile
Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.
Featured Stories
- Five stocks we like better than Aktis Oncology
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
